Elicera Therapeutics AB (ELIC) — Cash Flow Quality Index

Latest as of September 2025: -15.58x

Elicera Therapeutics AB (ELIC) has a Cash Flow Quality Index of -15.58x as of September 2025. Operating cash flow of Skr-4.74 Million is below net income of Skr304.15K, suggesting accrual-heavy earnings not yet converted to cash. Explore ELIC cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-15.58x

Operating CF / Net Income

Operating Cash Flow

Skr-4.74 Million

SEK

Net Income

Skr304.15K

SEK

Data as of

Sep 2025

Most recent filing

Annual Cash Flow Quality Index for Elicera Therapeutics AB (None–None)

Year-by-year earnings quality comparison for Elicera Therapeutics AB.

Year	Quality Index	Operating CF (SEK)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.